ABSTRACT

Objectives: This study presents a cost-effectiveness analysis comparing hydrophilic coated to uncoated catheters for patients performing urinary intermittent catheterisation. A national budget impact analysis is also included to evaluate the impact of intermittent catheterisation for management of bladder dysfunctions over a period of 5 years.

Design: A Markov model (lifetime horizon, 1 year cycle length) was developed to project health outcomes (life years and quality-adjusted life years) and economic consequences related to patients using hydrophilic coated or uncoated catheters. The model was populated with catheter-related clinical efficacy data retrieved from randomised controlled trials and quality-of-life data (utility weights) from the literature. Cost data (EUR, 2015) were estimated on the basis of healthcare resource consumption derived from an e-survey addressed to key opinion leaders in the field.

Setting: Italian Healthcare Service perspective.

Population: Patients with spinal cord injury performing intermittent urinary catheterisation in the home setting.

Main outcome measures: Incremental cost-effectiveness and cost-utility ratios (ICER and ICUR) of hydrophilic coated versus uncoated catheters and associated healthcare budget impact.

Results: The base-case ICER and ICUR associated with hydrophilic coated catheters were €20 761 and €24 405, respectively. This implies that hydrophilic coated catheters are likely to be cost-effective in comparison to uncoated ones, as proposed Italian threshold values range between €25 000 and €66 400. Considering a market share at year 5 of 89% hydrophilic catheters and 11% uncoated catheters, the additional cost for Italy is approximately €12 million in the next 5 years (current market share scenario for year 0: 80% hydrophilic catheters and 20% uncoated catheters).

Conclusions: Considered over a lifetime, hydrophilic coated catheters are potentially a cost-effective choice in comparison to uncoated ones. These findings can assist policymakers in evaluating intermittent catheterisation in patients with spinal cord injury.

INTRODUCTION

Injuries to the spinal cord (SCI) affect bladder functionality and cause motor or sensory deficits of a diverse nature and extent. Many of these conditions affect bladder functionality and cause what is known as a neurogenic bladder, often characterised by voiding problems. This clinical condition has a negative impact on health-related quality of life, and the associated economic costs can be overwhelming for patients already hampered with neurological problems. Healthcare usage may be excessive for these patients, including emergency department visits and subsequent hospitalisations.

In the community setting, the management of a neurogenic bladder frequently...
involves intermittent catheterisation (IC). With this technique, a catheter is temporarily used to remove urine from the bladder. As neurogenic bladder is often a permanent condition, IC may be required for a long period of time, often several times a day. There are different catheters available for IC, for example, disposable catheters with a hydrophilic polymer surface coating, disposable catheters with pre-packaged water-based lubricant (gel reservoir) and uncoated catheters. While there is a lack of strong evidence demonstrating the effectiveness of any particular catheter design, technique or strategy, the use of different kinds of catheters in the community may have different economic consequences. To the best of our knowledge, two cost-effectiveness studies have compared lifetime quality-adjusted life years (QALYs) and costs of different types of catheter from the UK perspective. Although both studies focused on the management of urinary tract infections (UTIs), the first based its analysis on the annual probability of experiencing at least one UTI for the different catheters considered (without taking into account the mean number of UTIs experienced in the same time by the patients’ cohort) and their short-term consequences. The second study focused on the average UTI rate per patient and month for hydrophilic coated and uncoated catheters and considered long-term sequelae such as kidney impairment. Considering a lifetime horizon, the study by Clark et al. showed that hydrophilic coated catheters are cost-effective when compared to uncoated catheters. Conversely, the study by Bermingham et al. reported that the reuse and cleansing of uncoated catheters is the most cost-effective alternative in comparison to all other catheter types. It should however be noted that reuse and cleaning of uncoated catheters may be regarded as an off-label procedure not supported by all regulating bodies. The divergent results from previous cost-effectiveness studies confirm that assumptions made, and the manner in which clinical data are chosen, highly affect the model construction and conclusions from the analysis, even in the same country setting.

One of the major advantages of IC is the significant reduction in the risk of catheter-associated UTIs, ensuring urinary tract health in general and preservation of kidney function in particular. Despite the efforts in reducing the risk of UTIs, they still cause high morbidity and frequent hospitalisations for people with neurogenic bladder. Repeated cycles of antibiotic therapy in patients with recurrent UTIs also contribute to ‘antibiotic resistance’, which in turn increases the need for new effective treatment options. For these reasons, UTIs entail a significant economic burden for patients, their families and healthcare systems.

Studies that attempted to estimate the burden of UTIs from the healthcare system perspective report costs ranging from €523 to €14167, with more complicated UTIs likely to be associated with higher costs. The high variability in costs relates to several aspects. For example, UTI definition (bacteriuria vs symptomatic UTI), study setting (hospital vs community), study population (general patients in hospital vs specific populations) and cost definitions can vary. The latter may consider direct healthcare costs only (eg, medications, therapies), or include indirect costs to society as productivity losses. The use of different payer perspectives (society and/or healthcare system) may also result in different UTI cost values.

In addition to the risk of UTI, IC performed several times a day poses a risk for urethral trauma. Urethral trauma can occur with or without the presence of haematuria and is associated with an increased risk of UTI. Damage to the urethra is less likely to occur with a lubricated catheter.

A catheter reducing the risks of urethral trauma and/or UTI may limit the economic burden for the healthcare system and may increase the quality of life for patients. A cost-effectiveness analysis (CEA) permits a systematic evaluation of the costs and quality-of-life consequences of different treatment regimens, highlighting the option that would have the highest net benefit.

The aim of this study was to perform a CEA from an Italian Healthcare Service perspective, comparing the two catheter types most frequently used for IC (ie, disposable hydrophilic coated or uncoated plastic catheters). This was done to add value to previously conflicting results of CEAs evaluating different catheter types, and to identify the most cost-effective catheter alternative for the Italian setting. A budget impact analysis (BIA) was also conducted to evaluate the impact on the Italian healthcare budget of IC for the management of bladder dysfunctions over a period of 5 years.

METHODS

The clinical effectiveness of each catheter was retrieved from randomised controlled trials (RCTs) focusing on the community perspective that were published in the literature. Cost data were estimated on the basis of diagnosis-specific healthcare resource usage, derived from an e-survey addressed to key opinion leaders in the field. Since clinical data were mainly reported for SCI patients, the model considered these as an applicable study population. The study focused mainly on UTIs and episodes of haematuria, as the former are the most frequent complications in patients performing IC, while the latter occur regularly in one-third of patients on a long-term basis.

Systematic literature review and clinical data synthesis

A systematic literature review was performed in June 2016 to retrieve RCTs, comparing hydrophilic coated and uncoated catheters for IC and reporting outcomes on UTIs and haematuria. A systematic search was conducted on PubMed, Embase, the Cochrane Library and Web of Science databases to retrieve clinical evidence (see online supplementary appendix for detailed search strategy and PRISMA statement).
In Italy, single-use catheters are considered the standard method for IC, and four catheters per day are delivered to users by local health agencies. Reuse of catheters is not present or relevant to the Italian healthcare system, so clinical evidence considering catheter reuse was discarded. Studies not reporting UTI frequencies per patient were also excluded. The studies by Cardenas et al. and Sarica et al. focused on SCI patients and reported data useful for the analysis. Data reported by Clark et al. derived from an internal report of the study conducted by De Ridder et al. were also included.

Table 1 reports UTI rates according to the methods presented in Clark et al., distinguishing the following settings: hospital period, community setting and combined scenario (hospital and community settings).

For haematuria, three studies reporting useful data were identified by the systematic literature search (table 2).

The model
As the management of patients performing IC is an evolving process, Markov multistate models were chosen for the health economic evaluation. A decision tree, combined with two Markov models, was designed to project lifetime health outcomes (life years and QALYs) and economic consequences related to SCI patients performing IC with hydrophilic or non-hydrophilic urinary catheters.

The Markov model (figure 1) includes the following health states: Alive, Symptomatic UTI, Haematuria and Death. A symptomatic UTI can either resolve or become an antibiotic-resistant UTI. In this case, the model distinguishes between first-line-resistant UTI, multidrug-resistant UTI and bacteraemia. Multidrug-resistant UTI and bacteraemia represent severe UTIs that can eventually cause patient death.

It is acknowledged that complications other than the ones included in the model health states may be relevant for patients practicing IC. For example, other infections and inflammations such as epididymo-orchitis, urethritis and prostatitis may occur as a complication of IC as well as strictures, false passage and bladder stones. The ‘Alive’ state accounts for baseline rates of these kinds of complications, which have been elicited by key opinion leaders in the field and assumed equal for hydrophilic coated and uncoated catheters (see details in the Results section—Healthcare resource consumption and costs).

A hypothetical cohort of 40-year-old, 80% male patients enters the Markov process in the ‘Alive’ state. Population characteristics are assumed to be similar to those previously reported for SCI patients performing IC in Italy.

<table>
<thead>
<tr>
<th>Study</th>
<th>Patients</th>
<th>Number of events</th>
<th>Rate per patient per month</th>
<th>Weighted mean</th>
<th>Rate ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hospital period</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncoated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardenas21</td>
<td>114</td>
<td></td>
<td>0.68</td>
<td>0.61</td>
<td>0.78</td>
</tr>
<tr>
<td>De Ridder23</td>
<td>61</td>
<td></td>
<td>0.55</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sarica22</td>
<td>10</td>
<td></td>
<td>0.27</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrophilic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardenas21</td>
<td>105</td>
<td></td>
<td>0.54</td>
<td>0.48</td>
<td></td>
</tr>
<tr>
<td>De Ridder23</td>
<td>60</td>
<td></td>
<td>0.44</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sarica22</td>
<td>10</td>
<td></td>
<td>0.07</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Community setting</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncoated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardenas20</td>
<td>23</td>
<td></td>
<td>0.14</td>
<td>0.14</td>
<td>0.47</td>
</tr>
<tr>
<td>Hydrophilic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardenas20</td>
<td>22</td>
<td></td>
<td>0.06</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td><strong>Combined scenario</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncoated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardenas20</td>
<td>23</td>
<td></td>
<td>0.14</td>
<td>0.40</td>
<td>0.92</td>
</tr>
<tr>
<td>Cardenas21</td>
<td>114</td>
<td></td>
<td>0.48</td>
<td></td>
<td></td>
</tr>
<tr>
<td>De Ridder23</td>
<td>61</td>
<td></td>
<td>0.38</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sarica22</td>
<td>10</td>
<td></td>
<td>0.27</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrophilic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardenas20</td>
<td>22</td>
<td></td>
<td>0.06</td>
<td>0.37</td>
<td></td>
</tr>
<tr>
<td>Cardenas21</td>
<td>105</td>
<td></td>
<td>0.48</td>
<td></td>
<td></td>
</tr>
<tr>
<td>De Ridder23</td>
<td>60</td>
<td></td>
<td>0.34</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sarica22</td>
<td>10</td>
<td></td>
<td>0.07</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

UTIs, urinary tract infections.
The model is mainly based on the structure presented by Bermingham et al. and focuses on short-term consequences of UTIs and haematuria. In contrast to Bermingham et al., who use the annual probability of experiencing at least one UTI, the current model incorporates the estimation of mean number of UTIs per patient and month as reported for Clark et al. to give a more precise estimate of costs and patients’ quality of life.

A 1-year Markov cycle length and a lifetime horizon were chosen for baseline analysis. To improve the accuracy of the results, a half-cycle correction was performed. The model was developed and analysed in Microsoft Excel.

### Model quantification

As described above, monthly rates of 0.14 and 0.06 were estimated for symptomatic UTIs in patients using uncoated catheters and hydrophilic coated catheters in the community setting, respectively. These data translate into 1.68 and 0.72 events per year and patient, respectively. For haematuria, 0.29 and 0.39 episodes per year and patient were estimated for uncoated and hydrophilic coated catheters, respectively.

The probabilities of clinical failure after treatment for symptomatic UTI reported by Clark et al. were mainly based on expert opinions, so annual transition probabilities as presented by Bermingham et al. were preferred. The annual probabilities of clinical failure, leading to first-line/multidrug-resistant UTI or bacteraemia, were applied to the mean number of symptomatic UTIs experienced by the patients over 1 year using uncoated or hydrophilic coated catheters.

As no further transition probabilities were found in literature, the model assumed that ‘multidrug-resistant UTI’ state also included healthcare resource consumption related to ‘first-line-resistant UTI’ state.

### Healthcare resource consumption and costs

As the analysis was performed from the Italian Healthcare System perspective, all costs related to the consumption of direct healthcare resources were estimated and expressed in euro (2015 value).

Clinical pathways and healthcare resource consumption for the management of symptomatic UTIs, first-line-resistant UTIs, multidrug-resistant UTIs, haematuria episodes and bacteraemia were estimated by study-specific questionnaire to urologists and neuro-urologists. All the clinicians (N=25) belonging to the NUS team (Italian spinal neuro-urologist group) of Fondazione
which treat the highest volumes of patients across Italy, received access to a web version of the questionnaire (developed with Qualtrics software) between 15 July 2015 and 15 October 2015 (a printed version of the questionnaire is available on request). The questionnaire included four sections: (1) introduction with a case vignette, (2) patient monitoring (relevant annual examinations, laboratory tests, visits, inpatient stays and drugs—irrespective of catheter type), (3) management of UTIs, bacteraemia and haematuria, and (4) future scenarios of catheter use. On the basis of their clinical experience, clinicians were asked to estimate healthcare usage, for example, the percentage of patients involved, regimen applied (outpatient, day-hospital or inpatient stay), daily dose and duration of drugs for general management.
and/or for management of an episode of UTI, bacterae mia and haematuria (drug costs are generally provided by an administrative office within the hospital).

The last section of the questionnaire included a forecast of possible future scenarios (1, 3 and 5 years) of usage of uncoated and hydrophilic coated catheters in Italy.

The results from the questionnaires were summarised to estimate healthcare resource usage. For each healthcare resource (examination, visit, hospitalisation, etc.) reported, a weighted mean was calculated on the basis of the number of responders.

The cost of resource consumption for the different events was calculated by multiplying the quantity of resources consumed by unit costs derived from official sources, that is, diagnosis-related groups’ (DRGs) reimbursement for hospitalisations, official tariffs for outpatient services, and hospital prices for drugs. When hospital prices for drugs were missing, a search was performed through the Italian Pharmaceutical Database (http://www.federfarma.it) reporting cost data for the National Healthcare Service.

Four catheters per day and patient were assumed, as this was the reimbursement level provided by the local health agencies. The unit cost was estimated from tender data at €1.70 and €0.25 for hydrophilic coated and uncoated catheters, respectively. In Italy, the lubricant gel for uncoated catheters is paid for by the patients, so this cost was omitted in the model.

During hospital stays, catheter costs are assumed included in the DRG reimbursement, excluding the need for additional device costs in the model.

### Quality-of-life estimates

The search for utility coefficients for SCI patients performing IC was performed through PubMed, Embase, Web of Science databases and the Cost-Effectiveness Analysis Registry. Two studies and a review were found that reported utility values for SCI patients experiencing UTIs. The first one reported utility values (estimated by HUI-Mark III health status classification system) of 0.28 and 0.15 for no/mild UTI and moderate/significant UTI, respectively. The second study reported utility values for UTI of 0.58 and 0.60 estimated by SF36 and SF12 questionnaires, respectively. The review included an additional study conducted by Vogel and Zebracki from which utility values of 0.831, 0.782 and 0.738 were estimated for no UTI, UTI and severe UTI, respectively. From the database search, no utility values were found for haematuria and bacterae mia health states.

Additional utility values were retrieved from Bermingham et al. and Clark et al. All values are summarised in online supplementary table S1.

The model included utility values referred to in the study by Bermingham et al. (see table 4).

For haematuria, a utility value of 0.738 (as for multidrug-resistant UTI state) was assumed.

The duration of the different events was estimated from the pharmacological treatment duration reported by the questionnaires, with the exception of both multidrug-resistant UTI and bacterae mia leading to death for which the length-of-stay threshold of the related DRGs was considered.

### Analyses

Both incremental cost-effectiveness and cost-utility ratios (ICER and ICUR) of hydrophilic coated versus uncoated catheters were calculated by dividing the incremental cost by the incremental health improvement. Life years, QALYs and costs were discounted with a 3.5% yearly rate. Transition probabilities, costs and utilities were entered into the model along with a distribution: beta for utilities and proportions of patients experiencing different kinds of UTIs, log-normal for relative risks and gamma for costs. Deterministic and probabilistic sensitivity analyses (PSA) were performed to test the robustness of the model. Univariate analyses were performed according to the main parameters; second-order Monte-Carlo analysis (1000 simulations) was conducted and the related acceptability curve was plotted.

Further analyses were performed that considered UTI rates for (1) hospital period and (2) combined (hospital plus community) scenario (based on data presented in table 1). Since UTI rates per patient per month vary across the retrieved studies, different scenario analyses were performed that considered data input from each study separately to evaluate heterogeneity. The same was performed for episodes of haematuria (based on data presented in table 2).

### Budget Impact Analysis

Based on the conclusion from the CEA model, a companion budget impact model was developed to address hypothetical changes to the Italian Healthcare Service budget considering an increased usage of hydrophilic coated catheters.

In order to perform the BIA, a review of epidemiological data focused on SCI patients performing IC was carried out.

The prevalence of SCI patients in Italy resulted in the range 60 000–70 000 according to a national registry; while the incidence (data from the Italian registry) showed a decrease from 20–25 to 7.8 per million inhabitants. Based on the study by Zlatev et al., it was assumed that 60% of patients perform IC. The total number of prevalent patients with SCI performing IC in Italy was estimated to be about 39 000 (65 000 × 60%), while the total number of incident patients was about 285. It was assumed that the distribution of the incident population was the same as that of the prevalent population (mean age of 40 years, 80% men).

The current scenario of patient distribution between the two devices under consideration was estimated from clinical input as 20% uncoated and 80% hydrophilic coated catheters. The estimation of the new scenario,
including an increased proportion of hydrophilic coated catheters in the years, was based on key opinion leaders’ replies to the questionnaire.

The cost of the current and new scenarios was determined by multiplying the cost for each intervention by the proportion of the eligible population using it, taking into account both prevalent and subsequent yearly incident cohorts. Financial streams were presented as undiscounted costs, since the focus of the analysis was expected budget at each point.34

RESULTS
Healthcare resource consumption and costs
A total of 9 of 25 clinicians completed the questionnaire, representing institutions with the highest volumes of treated SCI patients in Italy. The estimated healthcare resource usage is reported in online supplementary table S2. Reported care pathways were consistent with previous published literature.37

The ‘Alive’ health state in the model refers to usual patient year including control visits, examinations or hospitalisations for causes other than UTIs (eg, urethral strictures, bladder stones). All other health states consider healthcare resources consumption for management of a single event (eg, symptomatic UTI, haematuria, bacteraemia). For drugs, the mean dosage per patient was reported together with the proportion of administered patients.

Unit costs related to the healthcare resource consumption are summarised in online supplementary table S3.

The estimated event durations were 2 days for haematuria, 4 days for symptomatic UTI, additional 8 days for first-line-resistant UTI, additional 8 days for multidrug-resistant UTI (total 4+8+8+20 days), 37 days for hospitalisation for bacteraemia (DRG 576) and 65 days for infection leading to death (DRG 575).

In case of bacteraemia leading to patient death, the healthcare resources related to ‘infection leading to patient death’ (see online supplementary table S2) were applied (the management of the episode of bacteraemia is included in the DRG 575).

Summaries of event durations and costs estimated for the different health states/events are included in table 4.

Baseline results
Deterministic and probabilistic results were obtained from the model. It estimated an average life expectancy of 18.3 years (15.2 QALYs) for a study population using hydrophilic coated catheters and 17.3 years (14.3 QALYs) for a study population using uncoated catheters. The mean lifetime costs per patient were €82 915 and €62 457 for hydrophilic coated and uncoated catheters, respectively. For hydrophilic coated catheters, this resulted in an ICER of €20 761 and an ICUR of €24 405 (table 5—deterministic results). Although there is no official cost-effectiveness threshold for Italy, the reported proposed thresholds vary between €25 000–€40 000,38 €36 500,39 €60 000,40 and €66 400 (three times the Italian gross domestic product per capita according to the WHO).41 42 This suggests that the ICER/ICUR for hydrophilic coated catheters is lower than recommended threshold values and thus could be considered a cost-effective option.

Considering a lifetime horizon, hydrophilic coated catheters may reduce the frequency of UTIs by about 50% (from 48 to 24) in comparison to uncoated catheters. Considering the significant impact of UTIs, which account for about 23% to 63% of the total lifetime cost for SCI patients practicing intermittent catheterisation, prevention is of high importance.

A PSA was performed to account for uncertainty in cost-effectiveness calculations (online supplementary table S4 summarises the main model parameters with related probability distributions). Probabilistic model results are included in table 5.

The acceptability curve obtained from the Monte-Carlo simulation is shown in figure 2 for the ICUR. Given the varying Italian threshold values of €25 000–40 000, €36 500, €60 000 and €66 400, hydrophilic coated catheters have about a 47–86%, 77%, 97% and 98% probability of being cost-effective, respectively. Considering the UK-specific threshold value of £20 000–£30 000 recommended by NICE35 (equal to €26 400–€39 600 at an exchange rate of 1.32), hydrophilic coated catheters have a 48–86% probability of being cost-effective.

The scenario analyses performed considering weighted UTI rates for hospital period and combined (hospital plus community) settings resulted in ICURs equal to €11 908/QALY (ICER €10 097/LY) and €97 019/QALY (ICER €82 188/LY), respectively.

The additional scenario analyses conducted considering UTI rates from single studies, as reported in table 1, showed ICUR values for the hospital period that were equal to €11 240/QALY and €17 368/QALY, based on

<table>
<thead>
<tr>
<th>Table 5</th>
<th>Summary of the model results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Results</td>
<td>Catheter</td>
</tr>
<tr>
<td>Deterministic</td>
<td>Uncoated</td>
</tr>
<tr>
<td></td>
<td>Hydrophilic</td>
</tr>
<tr>
<td>Probabilistic</td>
<td>Uncoated</td>
</tr>
<tr>
<td></td>
<td>Hydrophilic</td>
</tr>
</tbody>
</table>

ICER, incremental cost-effectiveness ratio; ICUR, incremental cost-utility ratio; LY, life year; QALYs, quality-adjusted life years.
data from Cardenas et al (2011) and De Ridder et al (2005), respectively. Concerning the combined scenario, ICURs obtained were €21 184/QALY and €68 979/QALY based on data from Cardenas and Hoffman (2009) and De Ridder et al (2005), respectively. Only data from Cardenas et al (2011) showed the dominance of uncoated catheters, while data from Sarica et al (2010) showed hydrophilic catheter dominance for both hospital and hospital-plus-community settings.

Scenario analyses considering haematuria rates from single studies, as reported in table 2, showed limited variations in the ICUR, which ranged from €22 000/QALY (data from Sarica et al (2010)) to €24 569/QALY (data from De Ridder et al (2005)), respectively.

One-way sensitivity analyses were performed for the ICUR on the main model parameters. The results for the 10 parameters responsible for the main ICUR variations are presented in a tornado diagram in figure 3 (see online supplementary table S5 for complete results). The parameters with the greatest impact on ICUR were the relative risk (rate ratio) of developing a symptomatic UTI (for hydrophilic catheters vs uncoated catheters), the mean number of symptomatic UTIs per patient and year for uncoated catheters, the unit cost for hydrophilic catheters and the number of catheters used per day. For example, a rate ratio higher than 0.70 for developing a symptomatic UTI would result in ICUR values over €60 000. Hydrophilic coated catheters are the dominant choice if the unit cost is €0.85 or lower, but if the unit cost is €2.55, the ICUR exceeds €50 000. Also, lowering the utility value for the ‘Alive’ health state to 0.42 results in an ICUR above €65 000.

**Budget impact analysis**

As hydrophilic coated catheters are likely to be a cost-effective strategy, a BIA was performed to consider a new scenario with an increasing proportion of users of these advanced devices among patients performing IC in the next years. The proportions for possible future usages were estimated by the questionnaires. Focusing on uncoated and hydrophilic coated catheters only, the clinicians reported possible proportions of hydrophilic coated catheter use of 83%, 88% and 89% after 1, 3 and 5 years, respectively.

Table 6 reports the mean yearly cost per patient for both uncoated and hydrophilic coated catheters as calculated from the CEA model. Costs are presented for the following four sub-categories: patient monitoring (ie, control visits/examinations, etc.), management of UTIs, management of haematuria episodes, and catheters. The highest costs for uncoated catheters are related to the management of UTIs, while the highest costs for hydrophilic coated catheters are reported for the catheters themselves.

Table 7 reports the annual cost for SCI patients performing IC with either uncoated or hydrophilic coated catheters with related number of users (year 0: prevalent cohort, following years: incident cohorts), for both current and new scenarios. For both catheter types, the total cost per year has been weighted according to the proportion of use (ie, 80% hydrophilic coated and 20% uncoated catheters for all years in the current scenario.
and increasing percentage of use of hydrophilic catheters in the years in the new scenario). The last two columns summarise the total national healthcare budget and the yearly incremental cost. An increasing use of hydrophilic coated catheters results in an increase of the total budget of about €12 million in the next 5 years.

**DISCUSSION**

IC is considered the method of choice for the management of neurogenic bladder dysfunctions. Patients performing IC entail a substantial economic burden on the healthcare system, as infections and urethral trauma are common and result in frequent hospitalisations and high morbidity. Although different catheters are available with various characteristics in terms of medical safety, treatment functionality, patient comfort and environmental performance, there is currently no robust consensus as to which catheter type is the best. Recent meta-analyses investigating the impact of different catheter types on UTI rate and haematuria reported conflicting results. One study concluded that hydrophilic coated catheters are associated with a significant reduction in the risk of UTI and haematuria compared to non-hydrophilic catheters while another study was unable to differentiate between catheter types and techniques.

The aim of this study was to conduct cost-effectiveness and budget impact analyses of different catheters used for IC. The results were meant to support the process for deciding how to allocate scarce healthcare resources and maximise patients’ health while controlling costs. In Italy, the provision of disposable medical devices for daily repeated use, such as catheters for IC, is currently regulated by the Ministry of Health (MoH), which defines a list of medical devices supplied directly to patients and reimbursed by the Italian NHS. In recent times, the coverage of medical devices has been the subject of debates in Italy. The MoH has decided that more information is needed on the value contribution of medical devices both to patients and to the healthcare systems. For this reason, a National Health Technology Assessment Programme has been developed that refers to CEA as the main decision tool in measuring the incremental value of innovative technologies in comparison to the standard of care.

Considered a lifetime perspective, hydrophilic coated catheters resulted in an ICUR of €24 405/QALY and an ICER of €20 761/LY. Accordingly, hydrophilic coated catheters were likely to be considered cost-effective in comparison to uncoated catheters, given the available range of thresholds values proposed for Italy (from €25 000 to €66 400). PSA supported this findings: considering the Italian threshold values of €25 000–€40 000, €36 500, €60 000 and €66 400, hydrophilic coated catheters showed a 47–86%, 77%, 97% and 98% probability of being cost-effective, respectively.

The base-case findings are in line with conclusions reported by Clark and colleagues, who considered a UK setting and a cost-effectiveness threshold of £30 000 (about €40 000). However, the results differ from the report by Bermingham et al, who concluded that uncoated catheters are the most cost-effective when compared to all the other catheter types. This discrepancy is likely related to the difference in selecting studies and data for the underlying meta-analysis investigating UTI risk. Bermingham et al used data from a meta-analysis that estimated the risk of experiencing at least one UTI for each catheter type. Since there could be a great variation in the number of UTIs experienced by each patient, this assumption could potentially have hidden a risk-reducing efficacy related to hydrophilic coated catheters. A study evaluating self-reported catheter practices and associated problems for people mainly performing IC with uncoated catheters found an annual rate of 2.3 (95% CI 1.8 to 3) symptomatic UTIs treated with an antibiotic.

When a lower cost-effectiveness threshold was considered (ie, £20 000 to about £26 400), the probability that hydrophilic coated catheters may be a cost-effective choice was about 50%, partially supporting the conclusions presented by Bermingham et al.

Different from Clark et al, the present CE model focused only on short-term consequences of symptomatic UTIs, excluding lifetime effects on renal function. Since the probability of developing UTIs was found to be lower for hydrophilic coated catheters versus uncoated ones, this suggests that results are conservative.
Table 7  Budget impact analysis

<table>
<thead>
<tr>
<th></th>
<th>Uncoated catheters (UC)</th>
<th>Hydrophilic coated catheters (HC)</th>
<th>Incremental cost in comparison to current scenario</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>UC market share</td>
<td>UC users cohort</td>
<td>UC patients’ monitoring</td>
</tr>
<tr>
<td>Current scenario</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 20% 7800</td>
<td>€7 406 202</td>
<td>€17 553 353</td>
<td>€23 749</td>
</tr>
<tr>
<td>1 20% 57</td>
<td>€7 382 273</td>
<td>€17 496 692</td>
<td>€23 797</td>
</tr>
<tr>
<td>2 20% 57</td>
<td>€7 356 951</td>
<td>€17 436 723</td>
<td>€23 762</td>
</tr>
<tr>
<td>3 20% 57</td>
<td>€7 330 174</td>
<td>€17 373 319</td>
<td>€23 728</td>
</tr>
<tr>
<td>4 20% 57</td>
<td>€7 301 592</td>
<td>€17 305 645</td>
<td>€23 677</td>
</tr>
<tr>
<td>5 20% 57</td>
<td>€7 270 867</td>
<td>€17 232 905</td>
<td>€23 587</td>
</tr>
<tr>
<td>New scenario</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 20% 7800</td>
<td>€7 406 202</td>
<td>€17 553 353</td>
<td>€23 749</td>
</tr>
<tr>
<td>1 17% 48</td>
<td>€6 274 932</td>
<td>€14 872 189</td>
<td>€20 281</td>
</tr>
<tr>
<td>2 17% 48</td>
<td>€6 253 408</td>
<td>€14 821 214</td>
<td>€20 137</td>
</tr>
<tr>
<td>3 12% 34</td>
<td>€4 398 104</td>
<td>€10 423 991</td>
<td>€14 771</td>
</tr>
<tr>
<td>4 12% 34</td>
<td>€4 380 955</td>
<td>€10 383 387</td>
<td>€14 726</td>
</tr>
<tr>
<td>5 11% 31</td>
<td>€3 998 977</td>
<td>€9 478 098</td>
<td>€12 913</td>
</tr>
<tr>
<td>Total incremental cost</td>
<td>€11 873 774</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The findings of this study support the use of hydrophilic coated catheters but are limited to costs from a healthcare perspective. A broader evaluation, also including costs from a societal perspective, would increase the understanding of the economic sustainability of these devices.

Acknowledgements The authors would like to thank Dr Kristian Neovius for his support in the cost-effectiveness model design, Dr Michele Spinelli who made valuable suggestions in the questionnaire development and the clinicians who participated in the data collection: Elena Andretta, Sauro Biscotto, Mirella Giancroce, Gabriella Fizzotti, Alberto Manassero, Daniele Minardi, Oreste Risi, Sandro Sandri and Francesco Savoca.

Contributors Gabriella Fizzotti provided clinical advice for the manuscript preparation; Michele Spinelli provided suggestions in the questionnaire development.

Competing interests All authors have completed the Unified Competing Interests form at www.icmje.org/coiDisclosure.pdf (available on request from the corresponding author) and declare that CeRGas Bocconi has support from ASBM Srl for the submitted work.

Funding This study was funded by ASBM Srl through an unrestricted grant to CERGAS, Bocconi University, Via Roentgen 1, 20136 Milan, Italy. The study sponsor had no role in the study design; the collection, analysis and interpretation of data; the writing of the report; or the decision to submit the article for publication. No interferences occurred in carrying out the research project, or in writing the manuscript that is the sole responsibility of the authors.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Additional data are available in online supplementary appendix.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES